// App-Quantinova.ai

336 : Lenalidomide, Bortezomib, and Dexamethasone (RVD) in Combination with Vorinostat As Front-Line Therapy for Patients with Multiple Myeloma (MM): Results of a Phase 1 Study

Researchers

Presenter

  • Jatin J. Shah

Principal Investigators

  • Jacob P. Laubach

  • Paul G. Richardson

  • Robert Z. Orlowski

  • Sagar Lonial

  • Alaina R. Mitchell

  • Cathy Sharp

  • Colleen Lewis

  • R. Donald Harvey

  • Charise Gleason

  • Daniela Casbourne

  • Ajay K. Nooka

  • Leonard T Heffner

Medical Centers

  • Winship Cancer Institute of Emory University, Atlanta, GA

  • LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Research, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA

  • The Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

  • Department of Lymphoma and Myeloma, University of Texas M. D. Anderson Cancer Center, Houston, TX

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

  • Cardiovascular (CVS)

Disease

  • Venous thrombosis

  • Cardiac arrest

  • Multiple Myeloma

  • Thrombocytopenia

  • Constipation

  • Neutropenia

  • Peripheral neuropathy

  • Syncope

Biomarkers

  • N/A

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Lenalidomide

  • Bortezomib

  • Vorinostat

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved